A druggable addiction to <i>de novo</i> pyrimidine biosynthesis in diffuse midline glioma
Sharmistha Pal(Dana-Farber Cancer Institute), Daphne A. Haas‐Kogan(Neurology, Inc)
Cited by 0
Related Papers
Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide
|Neuro-Oncology|2011|158
H3K27M-driven hypertranscription leads to a new targetable dependency in diffuse midline gliomas
|bioRxiv (Cold Spring Harbor Laboratory)|2026|0